Inflammatory Bowel Disease: Clinical Diagnosis and Surgical Management: 2nd Edition

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Gastroenterology & Hepatology".

Deadline for manuscript submissions: 31 May 2024 | Viewed by 2154

Special Issue Editor


E-Mail Website
Guest Editor
Department of Biochemistry, Cancer Biology, Neuroscience and Pharmacology, Meharry Medical College School of Medicine, Nashville, TN 37208-3500, USA
Interests: inflammatory bowel disease; ulcerative colitis; Crohn's colitis; indeterminate colitis; endoscopic medicine; molecular diagnostics; biomarker; colonic ileal metaplasia; precision diagnostics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

It is our pleasure to invite scholars working in the areas of clinical diagnostics and surgical management of inflammatory bowel disease (IBD) to submit their valuable research papers to this Special Issue of Medicina, an open access MDPI journal.

Predominantly, colonic inflammatory bowel disease (IBD) encompasses ulcerative colitis (UC) and Crohn’s colitis (CC); when the diagnostic classification for these two diseases is inconclusive, the condition is termed indeterminate colitis (IC). Thus, discrimination of IBD into specific subtypes with high accuracy is a key medical challenge because the surgical care of patients is significantly dependent on it. Classification of IC either as UC or CC is of utmost importance when determining a patient’s candidacy for pouch surgery, i.e., restorative proctocolectomy and ileal pouch–anal anastomosis (RPC-IPAA). Hence, studies on disease mechanisms as well as functional outcomes of RPC-IPAA are highly encouraged.

Patients with medical refractory disease often undergo RPC-IPAA. This intervention involves the removal of the entire colon and rectum while preserving bowel continuity, evacuation, continence/deferral, discrimination, and fertility; long-term functional results of this surgery are excellent. The challenges of diagnostic ambiguity and delay in colonic IBD is a grave and unsolved issue, which is associated with an increased risk of adverse outcomes. However, recent findings in the areas of ectopic colonic ileal metaplasia and DEFA5 (alias HD5) expansion seems promising (PMID: 33690604 and PMID: 28817680).

Dr. Amosy E M'Koma
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • inflammatory bowel disease
  • clinical diagnostics
  • colorectal surgery
  • Crohn’s colitis
  • ulcerative colitis

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

14 pages, 2195 KiB  
Review
Post-COVID-19 and Irritable Bowel Syndrome: A Literature Review
by Daniel Paramythiotis, Eleni Karlafti, Matthaios Didagelos, Maria Fafouti, Kalliopi Veroplidou, Adonis A. Protopapas, Georgia Kaiafa, Smaro Netta, Antonios Michalopoulos and Christos Savopoulos
Medicina 2023, 59(11), 1961; https://doi.org/10.3390/medicina59111961 - 06 Nov 2023
Viewed by 1903
Abstract
The emergence of post-COVID-19 syndrome (PCS), a complex and multifactorial condition that follows the acute COVID-19 infection, has raised serious concerns within the global medical community. Concurrently, Irritable Bowel Syndrome (IBS), a widespread chronic gastrointestinal (GI) dysfunction, is considered to be one of [...] Read more.
The emergence of post-COVID-19 syndrome (PCS), a complex and multifactorial condition that follows the acute COVID-19 infection, has raised serious concerns within the global medical community. Concurrently, Irritable Bowel Syndrome (IBS), a widespread chronic gastrointestinal (GI) dysfunction, is considered to be one of the most common disorders of gut–brain interaction (DGBI) that significantly affects the quality of life and social functioning of patients. PCS presents a wide range of symptoms and GI manifestations, including IBS. This review aims to analyze the GI involvement and the prolonged symptoms of COVID-19 infection as part of PCS, in order to explore the potential development of post-infection IBS (PI-IBS) in COVID-19 patients. Irritating factors such as enteric infection, psychosocial conditions, food antigens, and antibiotics may lead to abnormalities in the physiological function of the GI system and could be involved in the development of PI-IBS. Through the presentation of the pathophysiological mechanisms and epidemiological studies that assessed the prevalence of IBS as part of PCS, we attempted to provide a better understanding of the long-term consequences of COVID-19 and the pathogenesis of PI-IBS. Even though PI-IBS is becoming a global challenge, there are only a few studies about it and therefore limited knowledge. Currently, the majority of the existing treatment options are referred to non-COVID-19-associated DGBIs. Forthcoming studies may shed light on the mechanisms of PI-IBS that could be targeted for treatment development. Full article
Show Figures

Figure 1

Back to TopTop